Shares of Intensity Therapeutics Inc. (NASDAQ:INTS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the four ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $37.50.
A number of equities analysts have commented on INTS shares. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Tuesday, July 21st. Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. Finally, Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th.
Get Our Latest Research Report on Intensity Therapeutics
Intensity Therapeutics Trading Up 4.8%
Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, equities analysts expect that Intensity Therapeutics will post -2.7 earnings per share for the current year.
Institutional Investors Weigh In On Intensity Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares during the last quarter. Mesirow Financial Investment Management Inc. increased its holdings in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after acquiring an additional 51,000 shares during the period. Legacy Advisors LLC acquired a new stake in shares of Intensity Therapeutics in the 4th quarter worth about $63,000. State Street Corp lifted its position in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after purchasing an additional 121,700 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in Intensity Therapeutics in the 4th quarter valued at about $41,000. 3.74% of the stock is owned by institutional investors and hedge funds.
About Intensity Therapeutics
Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.
Recommended Stories
- Five stocks we like better than Intensity Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
